Vascular Dementia Clinical Trial
Official title:
Retinal Vessel Leakage in Cerebral Small Vessel Disease: a Sub-study of the Mild Stroke Study 3
The goal of this observational study is to learn about leakage from retinal vessels in cerebral small vessel disease. The main questions it aims to answer are: - Does retinal vessel leakage occur in cerebral small vessel disease? - If it does, is the severity of retinal vessel leakage similar to the severity of cerebral small vessel disease generally? Participants will be tested using fluorescein angiography. This involves an intravenous injection of fluorescent dye, and is a very sensitive way to find leakage from retinal blood vessels. Participants will have already had brain scans and other examinations and tests to measure the severity of their cerebral small vessel disease. Our new retinal images will complement the information from these previous tests.
Cerebral small vessel disease (SVD) is a common cause of stroke and dementia. The molecular causes are unclear, limiting new therapies. Breakdown of the blood-brain barrier (BBB) is characteristic and may damage brain tissue. However, specialist MRI scans to measure BBB breakdown are expensive and time-consuming. In contrast, measuring leakage from retinal blood vessels is relatively simple. The blood-retina barrier is very similar to the BBB, and SVD is likely to damage retinal and brain blood vessels in the same way. If so, then retinal angiography could be used to study SVD pathogenesis and measure the effect of new treatments with much greater resolution and lower cost than MRI. We have three aims: 1. Test the feasibility of fluorescein angiography in people with SVD 2. Discover if retinal vessel leakage occurs people with SVD 3. Discover whether the severity of retinal vessel leakage is associated with clinical features of SVD We will recruit participants from a well-established cohort of people with SVD - the Mild Stroke Study 3 (MSS3). ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04567745 -
Automated Retinal Image Analysis System (EyeQuant) for Computation of Vascular Biomarkers
|
Phase 1 | |
Recruiting |
NCT04109963 -
Trial of Remote Ischemic Pre-conditioning in Vascular Cognitive Impairment
|
Phase 2 | |
Recruiting |
NCT04335994 -
ENhancing Outcomes in Cognitive Impairment Through Use of Home Sleep ApNea Testing
|
N/A | |
Completed |
NCT01761227 -
Efficacy and Safety of Fufangdanshen Tablets in Mild to Moderate Vascular Dementia
|
Phase 2 | |
Active, not recruiting |
NCT01208675 -
The Swedish BioFINDER Study
|
||
Completed |
NCT00165763 -
Efficacy and Safety of Donepezil Hydrochloride (Aricept) in Vascular Dementia
|
Phase 4 | |
Completed |
NCT00621647 -
Seroquel- Agitation Associated With Dementia
|
Phase 3 | |
Recruiting |
NCT04095962 -
Effects of a Multicomponent Exercise Intervention on Physical and Cognitive Function of Older Adults With Dementia
|
N/A | |
Recruiting |
NCT03275363 -
The University of Hong Kong Neurocognitive Disorder Cohort
|
N/A | |
Active, not recruiting |
NCT03804229 -
Efficacy and Safety of Butylphthalide Soft Capsule for the Treatment of Vascular Dementia
|
Phase 3 | |
Enrolling by invitation |
NCT03724136 -
Alzheimer's Autism and Cognitive Impairment Stem Cell Treatment Study
|
N/A | |
Completed |
NCT02453932 -
Efficacy and Safety of Tianzhi Granule in Mild to Moderate Vascular Dementia
|
Phase 3 | |
Completed |
NCT00947531 -
A Clinical Trial to Evaluate the Safety and Efficacy of 20 ml Cerebrolysin in Patients With Vascular Dementia
|
Phase 4 | |
Not yet recruiting |
NCT03702543 -
Managing Vascular Dementia Risk Factors With SymTrend
|
Phase 1 | |
Enrolling by invitation |
NCT02147652 -
Personalized Music Therapy and Agitation in Dementia
|
N/A | |
Recruiting |
NCT04114994 -
Longitudinal Cognitive Assessment by BoCA
|
||
Recruiting |
NCT06034509 -
Cognitive and Vascular Functioning Following TBI
|
||
Recruiting |
NCT05921266 -
Urolithin A Supplementation in Middle-aged Adults With Obesity
|
N/A | |
Completed |
NCT01465360 -
Performance of AclarusDx™, a Blood-Based Transcriptomic Test for AD, in US Patients Newly Referred to a Memory Center
|
N/A | |
Not yet recruiting |
NCT01466543 -
Effect of Zydena (Udenafil) on Cerebral Blood Flow and Peripheral Blood Viscosity
|
Phase 2 |